Showing 1181-1190 of 10142 results for "".
Internal and External Healing: The Rise of After-Sun Care
https://practicaldermatology.com/topics/skin-cancer-photoprotection/internal-and-external-healing-the-rise-of-after-sun-care/27165/Internal and External Healing: The Rise of After-Sun CareDermWireTV: PCA to Space Station; ASDS Pandemic Data; LaRoche-Posay, GW Partnership
https://practicaldermatology.com/topics/practice-management/dermwiretv-pca-to-space-station-asds-pandemic-data-laroche-posay-gw-partnership/20059/The "Great Resignation" forcing some dermatology practices to operate with reduced staffing is just one of the lingering impacts of the COVID-19 pandemic on practices, according to results of a survey by the American Society for Dermatologic Surgery. PCA skin is sending the first-ever private sectorUpdates from Principia, Sebacia, and Candela
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-updates-from-principia-sebacia-and-candela/19571/Phase 2 data for from the Believe-PV study for PRN1008 show that the investigational agent from Principia Biopharma reached the primary efficacy measure in pemphigus. Data confirm that Sebacia microparticles confer benefit in the management of acne vulgaris in real-world settings. Candela has rebranExploring the Benefits of Nitric Oxide for Hair Loss Patients Through REVIAN® Red
https://practicaldermatology.com/topics/hair-nails/exploring-the-benefits-of-nitric-oxide-for-hair-loss-patients-through-revian-red/19753/Learn more about the mechanism of action of the new REVIAN Red Dual-Band LED light therapy cap and what makes it unique from other at-home FDA-cleared devices. REVIAN Red is indicated to treat androgenetic alopecia and to promote hair growth in males who have Norwood-Hamilton classifications of IIaNoah Worcester 2024: Dr. Gold on Toxins
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-gold-toxins/24583/Noah Worcester 2024: Dr. Gold on ToxinsDeveloping Core Outcome Sets: The Importance of Common Standards for Clinical Studies of Specific Diseases and Conditions
https://practicaldermatology.com/topics/feature/developing-core-outcome-sets-importance-common-standards-clinical-studies-specific-diseases-and-conditions/26654/Developing Core Outcome Sets: The Importance of Common Standards for Clinical Studies of Specific Diseases and ConditionsDermWireTV: Meet Crown Aesthetics, Revance to Market Teoxane Fillers, Almirall Collaborates
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-meet-crown-aesthetics-revance-to-market-teoxane-fillers-almirall-collaborates/19719/On the heels of recent acquisitions, Crown Laboratories is reorganizing and rebranding as three divisions: Crown Aesthetics, Crown Beauty, and Crown Therapeutics. Revance gains immediate and exclusive rights to commercialize Teoxane’s RHA 2, RHA 3, and RHA 4 products, which include lidocaine. A fourFrom SDPA: JAKs, Black Boxes, and What It All Means
https://practicaldermatology.com/conferences/sdpa-2024/sdpa-jaks-black-boxes-and-what-it-all-means/26286/Practitioners shouldn’t fear Janus kinase (JAK) inhibitors for their patients when appropriate, according to a wide-ranging expert chat at the 2024 SDPA Annual Summer Conference in San Diego. The conversation featured Matthew Zirwas, MD, a dermatologist with DOCS Dermatology, and Amy Spizuoco, DO, FDermWireTV: Sanofi Genzyme & Regeneron Global AD Report; Hydroquinone; Pfizer NDA; VCS
https://practicaldermatology.com/topics/practice-management/dermwiretv-sanofi-genzyme-regeneron-global-ad-report-hydroquinone-pfizer-nda-vcs/19868/The “Improving Quality of Care in AD” report, commissioned and funded by Sanofi Genzyme & Regeneron and completed by KPMG, debuts at the annual meeting of the EADV. Changes to FDA regulations implemented as part of the CARES Act limit access to hydroquinone. This year’s Virtual Vegas Cosmetic SuGalderma's Future, Allergan's Bonti Buy, and Sebacia Clearance
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-galderma-s-future-allergan-s-bonti-buy-and-sebacia-clearance--xgheloga/18233/Nestle's Board says it has come to the conclusion that the future growth opportunities of Nestlé Skin Health lie increasingly outside the Group's strategic scope and expects a review of strategic options for Nestlé Skin Health to be complete by mid-2019. Allergan is acquiring Bonti for 195 million d